Nanolipidic particle assembly populations
Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.
1. NLPs (Nanolipidic Particles) formed from
a hydrous monophasic precursor solution made of phospholipids, a first concentration of aqueous solvent, and a first concentration of non-aqueous solvent selected from the group consisting of ethanol, 1-propanol, and 2-propanol,
a second concentration of non-aqueous solvent incorporated into said hydrous monophasic precursor solution,
a second concentration of aqueous solvent incorporated into said hydrous monophasic precursor solution,
thereby yielding NLPs that are sized from about 1 nm to about 20 nm and self-stabilizing by the retention of said second concentration of the aqueous solvent in said NLPs, said NLPs having a retained total concentration of said non-aqueous solvent being from about 0.5% to about 14%.
2. The NLPs of claim 1 , wherein said non-aqueous solvent is ethanol.
3. The NLPs of claim 1 , wherein said phospholipids are selected from the group consisting of phosphatidyl choline (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
4. The NLPs of claim 1 , wherein said non-aqueous solvent is ethanol, and said phospholipids are selected from the group consisting of phosphatidyl choline (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
5. The NLPs of claim 1 , wherein said NLPs are for oral consumption.
6. The NLPs of claim 4 , wherein said NLPs are for oral consumption.
7. The NLPs of claim 1 , wherein said NLPs are for topical application.
8. The NLPs of claim 4 , wherein said NLPs are for topical application.
9. Nanolipidic Particles (NLPs) having a passenger molecule, comprising particles formed from:
a. a hydrous monophasic precursor solution having phospholipids, a first concentration of water, and a first concentration of a non-aqueous solvent selected from the group consisting of ethanol, 1-propanol, and 2-propanol,
b. a second concentration of a non-aqueous solvent incorporated into said particles in said monophasic precursor solution,
c. a second concentration of an aqueous solvent incorporated into said particles in said monophasic precursor solution having said second concentration of non-aqueous solvent incorporated therein;
wherein said NLPs are stabilized for at least two years at a size range of about 1 nm to about 20 nm by the retention of said second concentration of aqueous solvent in said NLPs, and wherein said NLPs have a retention of a total concentration of said non-aqueous solvent from about 0.5% to about 14%, with a passenger molecule encapsulated in said particle.
10. The NLPs of claim 9 , wherein said non-aqueous solvent is ethanol.
11. The NLPs of claim 9 , wherein said phospholipids are selected from the group consisting of phosphatidyl choline (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
12. The NLPs of claim 9 , wherein said NLPs are for oral consumption.
13. The NLPs of claim 9 , wherein said NLPs are for topical application.
14. The NLPs of claim 9 , wherein said non-aqueous solvent is ethanol, and said phospholipids are selected from the group consisting of phosphatidyl choline (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
15. The NLPs of claim 14 , wherein said NLPs are for oral consumption.
16. The NLPs of claim 14 , wherein said NLPs are for topical application.
17. Nanolipidic Particles (NLPs) comprising particles formed from:
(a) a hydrous monophasic precursor solution having phospholipids, a first concentration of water, and a first concentration of a non-aqueous solvent selected from the group consisting of ethanol, 1-propanol, and 2-propanol,
(b) a second concentration of a non-aqueous solvent; and,
(c) a second concentration of an aqueous solvent,
resulting in said NLPs retaining said second concentration of aqueous solvent in said NLPs, and wherein said NLPs have a total concentration of said non-aqueous solvent from about 0.5% to about 14% and are sized from about 1 nm to 20 nm.
18. The NLPs of claim 17 , wherein said non-aqueous solvent is ethanol.
19. The NLPs of claim 17 , wherein said phospholipids are selected from the group consisting of phosphatidyl choline (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
20. The NLPs of claim 17 , wherein said NLPs are for oral consumption.
21. The NLPs of claim 17 , wherein said NLPs are for topical application.
22. The NLPs of claim 17 , wherein said non-aqueous solvent is ethanol, and said phospholipids are selected from the group consisting of phosphatidyl choline (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixture thereof.
23. The NLPs of claim 22 , wherein said NLPs are for oral consumption.
24. The NLPs of claim 22 , wherein said NLPs are for topical application.
25. NLPs (Nanolipidic Particles) formed from:
(a) a hydrous monophasic precursor solution having phospholipids, a first concentration of water, and a first concentration of a non-aqueous solvent selected from the group consisting of ethanol, 1-propanol, and 2-propanol,
(b) a second concentration of said non-aqueous solvent incorporated into said hydrous monophasic precursor solution, and,
(c) a second concentration of said aqueous solvent incorporated into said hydrous monophasic precursor solution,
thereby producing NLPs stably sized from 1 nm to 20 nm, wherein said NLPs retain said second concentration of said aqueous solvent in said NLPs ranging from a 1:1 to 20:1 ratio of water to phospholipids and wherein said NLPs retain a total concentration of said non-aqueous solvent from about 0.5% to about 14%.
26. The NLPs of claim 25 , wherein said non-aqueous solvent is ethanol.
27. The NLPs of claim 25 , wherein said phospholipids are selected from the group consisting of phosphatidyl choline (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixture thereof.
28. The NLPs of claim 25 , wherein said non-aqueous solvent is ethanol, and said phospholipids are selected from the group consisting of phosphatidyl choline (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
29. The NLPs of claim 25 , wherein a passenger molecule is encapsulated within said NLPs.
30. NLPs (Nanolipidic Particles) comprising particles formed from:
(a) a hydrous monophasic precursor solution, said hydrous monophasic precursor consisting essentially of phospholipids, a first concentration of water and a first concentration of non-aqueous solvent selected from the group containing ethanol, 1-propanol and 2-propanol,
(b) a second concentration of a non-aqueous solvent; and,
(c) a second concentration of an aqueous solvent,
thereby yielding NLPs independently shelf stably sized from 1 nm to 20 nm by the incorporation and retention of said second concentration of said aqueous solvent, said NLPs having retained a total concentration of non-aqueous solvent from about 0.5% to about 14%.
31. The NLPs of claim 30 , wherein the NLPs are sized from 6 nm to 12 nm.
32. The NLPs of claim 30 , wherein said non-aqueous solvent is ethanol.
33. The NLPs of claim 30 , wherein said non-aqueous solvent is ethanol, and said phospholipids are selected from the group consisting of phosphatidyl choline (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
34. The NLPs of claim 30 , wherein a passenger molecule is encapsulated within said NLPs.